Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism

NAEnrolling by invitationINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Pubertal DelayHypogonadism, HypogonadotropicConstitutional Delay in Growth and Puberty (CDGP)
Interventions
DIAGNOSTIC_TEST

Triptorelin (GnRH agonists)

"1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)"

Trial Locations (1)

1425

Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires

All Listed Sponsors
lead

Hospital de Niños R. Gutierrez de Buenos Aires

OTHER